Skip to main content
Top
Published in: Drugs & Aging 1/2013

01-01-2013 | Review Article

Managing Older Patients with Coexistent Asthma and Chronic Obstructive Pulmonary Disease

Diagnostic and Therapeutic Challenges

Authors: Vanessa M. McDonald, Isabel Higgins, Peter G. Gibson

Published in: Drugs & Aging | Issue 1/2013

Login to get access

Abstract

Asthma and chronic obstructive pulmonary disease (COPD) are common obstructive airway diseases, especially among older people. These conditions are associated with a significant and increasing disease burden. The diagnosis and management of asthma and COPD in older populations are complex, and consequently clinicians are faced with many therapeutic and diagnostic challenges. Both aging and obstructive airway diseases are associated with complex co-morbidities and these coexisting illnesses confound management. Moreover, the age-related physiological changes that occur in the lungs may lead to airflow limitation, and this may be difficult to distinguish from an active disease state. In practice, management of asthma and COPD is informed by disease-specific clinical practice guidelines; however, most older people with these conditions are excluded from clinical trials that are designed to inform practice, creating major evidence gaps. Furthermore, seldom do clinical practice guidelines consider the complexities of management in older populations. The problems experienced by older people are complex and multifactorial and our approach to management must reflect these challenges. Opportunities exist to improve the management and outcomes for older people with obstructive airway disease and there is an urgent need for clinical trials to test management approaches in this population; current research must consider the challenges and evidence gaps that exist.
Literature
1.
go back to reference Gibson PG, McDonald VM, Marks GB. Asthma in the older adult. Lancet. 2010;374(9743):803–13.CrossRef Gibson PG, McDonald VM, Marks GB. Asthma in the older adult. Lancet. 2010;374(9743):803–13.CrossRef
2.
go back to reference McDonald VM, Simpson JL, Higgins I, et al. Multidimensional assessment of older people with asthma & COPD: clinical management and health status. Age Ageing. 2011;40(1):42–9.PubMedCrossRef McDonald VM, Simpson JL, Higgins I, et al. Multidimensional assessment of older people with asthma & COPD: clinical management and health status. Age Ageing. 2011;40(1):42–9.PubMedCrossRef
3.
go back to reference Cosio BG, Agusti A. Comorbidity: a distinctive feature of elderly respiratory patients. Eur Respir Mon. 2009;43:205–16.CrossRef Cosio BG, Agusti A. Comorbidity: a distinctive feature of elderly respiratory patients. Eur Respir Mon. 2009;43:205–16.CrossRef
4.
go back to reference Hanania NA, King MJ, Braman SS, et al. Asthma in the elderly: current understanding and future research needs—a report of a National Institute on Aging (NIA) workshop. J Allergy Clin Immunol. 2011;128(3 Suppl):S4–24.PubMedCrossRef Hanania NA, King MJ, Braman SS, et al. Asthma in the elderly: current understanding and future research needs—a report of a National Institute on Aging (NIA) workshop. J Allergy Clin Immunol. 2011;128(3 Suppl):S4–24.PubMedCrossRef
5.
go back to reference McDonald VM, Gibson PG. Asthma mortality and management in older Australians: time for a new approach? Australas J Ageing. 2008;27:215.PubMedCrossRef McDonald VM, Gibson PG. Asthma mortality and management in older Australians: time for a new approach? Australas J Ageing. 2008;27:215.PubMedCrossRef
6.
go back to reference Australian Centre for Asthma Monitoring. Asthma in Australia 2008. Canberra: Australian Institute of Health and Welfare; 2008. Contract No.: Report No. ACM 14. Australian Centre for Asthma Monitoring. Asthma in Australia 2008. Canberra: Australian Institute of Health and Welfare; 2008. Contract No.: Report No. ACM 14.
7.
go back to reference Navaratnam P, Jayawant SS, Pedersen CA, et al. Asthma pharmacotherapy prescribing in the ambulatory population of the United States: evidence of nonadherence to national guidelines and implications for elderly people. J Am Geriatr Soc. 2008;56(7):1312–7.PubMedCrossRef Navaratnam P, Jayawant SS, Pedersen CA, et al. Asthma pharmacotherapy prescribing in the ambulatory population of the United States: evidence of nonadherence to national guidelines and implications for elderly people. J Am Geriatr Soc. 2008;56(7):1312–7.PubMedCrossRef
8.
go back to reference Hill K, Goldstein RS, Guyatt GH, et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ. 2010;182(7):673–8.PubMedCrossRef Hill K, Goldstein RS, Guyatt GH, et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ. 2010;182(7):673–8.PubMedCrossRef
9.
go back to reference Bednarek M, Maciejewski J, Wozniak M, et al. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008;63(5):402–7.PubMedCrossRef Bednarek M, Maciejewski J, Wozniak M, et al. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008;63(5):402–7.PubMedCrossRef
10.
go back to reference Buist SA, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet. 2007;370:741–50.PubMedCrossRef Buist SA, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet. 2007;370:741–50.PubMedCrossRef
11.
go back to reference Antonelli Incalzi R, Pedone C, Pahor M. Multidimensional assessment and treatment of the elderly with COPD. Eur Respir Mon. 2009(43):35–55. Antonelli Incalzi R, Pedone C, Pahor M. Multidimensional assessment and treatment of the elderly with COPD. Eur Respir Mon. 2009(43):35–55.
12.
go back to reference Beasley R, Weatherall M, Travers J, et al. Time to define the disorders of the syndrome of COPD. Lancet. 2009;29:670–2.CrossRef Beasley R, Weatherall M, Travers J, et al. Time to define the disorders of the syndrome of COPD. Lancet. 2009;29:670–2.CrossRef
13.
go back to reference Guerra S. Asthma and chronic obstructive pulmonary disease. Curr Opin Allergy Clin Immunol. 2009;9:409–16.PubMedCrossRef Guerra S. Asthma and chronic obstructive pulmonary disease. Curr Opin Allergy Clin Immunol. 2009;9:409–16.PubMedCrossRef
14.
go back to reference Fabbri LM, Luppi F, Beghé B, et al. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31:204–12.PubMedCrossRef Fabbri LM, Luppi F, Beghé B, et al. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31:204–12.PubMedCrossRef
15.
go back to reference Marks GB, Poulos LM, Jenkins CR, et al. Asthma in older adults: a holistic, person centred and problem oriented approach. Med J Aust. 2009;191(4):197–9.PubMed Marks GB, Poulos LM, Jenkins CR, et al. Asthma in older adults: a holistic, person centred and problem oriented approach. Med J Aust. 2009;191(4):197–9.PubMed
16.
go back to reference United Nations. Report of the Second World Assembly on Ageing. Madrid, Spain: United Nations; 2002. United Nations. Report of the Second World Assembly on Ageing. Madrid, Spain: United Nations; 2002.
17.
go back to reference Productivity Commission. Economic implications of an ageing Australia, research report. Canberra: Commonwealth of Australia; 2005. Productivity Commission. Economic implications of an ageing Australia, research report. Canberra: Commonwealth of Australia; 2005.
18.
go back to reference Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross sectional surveys. Lancet. 2006;368(9537):733–43.PubMedCrossRef Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross sectional surveys. Lancet. 2006;368(9537):733–43.PubMedCrossRef
19.
go back to reference Bellia V, Scichilone N, Battaglia S. Asthma in the elderly. Eur Respir Mon. 2009;43:56–76.CrossRef Bellia V, Scichilone N, Battaglia S. Asthma in the elderly. Eur Respir Mon. 2009;43:56–76.CrossRef
20.
go back to reference Sharma G, Goodwin J. Effect of aging on respiratory system physiology and immunology. Clin Interv Aging. 2006;1(3):253–60.PubMedCrossRef Sharma G, Goodwin J. Effect of aging on respiratory system physiology and immunology. Clin Interv Aging. 2006;1(3):253–60.PubMedCrossRef
21.
go back to reference Berend N. Normal ageing of the lung: implications for diagnosis and monitoring of asthma in older people. Med J Aust. 2005;183(1 Suppl):S28–9.PubMed Berend N. Normal ageing of the lung: implications for diagnosis and monitoring of asthma in older people. Med J Aust. 2005;183(1 Suppl):S28–9.PubMed
22.
go back to reference De Martinis M, Franceschi C, Monti D, et al. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett. 2005;579(10):2035–9.PubMedCrossRef De Martinis M, Franceschi C, Monti D, et al. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett. 2005;579(10):2035–9.PubMedCrossRef
23.
go back to reference Meyer KC, Rosenthal NS, Sorergel P, et al. Neutrophils and low grade inflammation in the seemingly normal aging human lung. Mech Aging Dev. 1998;104(2):169–81.PubMedCrossRef Meyer KC, Rosenthal NS, Sorergel P, et al. Neutrophils and low grade inflammation in the seemingly normal aging human lung. Mech Aging Dev. 1998;104(2):169–81.PubMedCrossRef
24.
go back to reference Thompson AB, Scholer SG, Daughton DM, et al. Altered epithelial lining fluid parameters in old normal individuals. J Gerontol. 1992;47(5):M171–6.PubMedCrossRef Thompson AB, Scholer SG, Daughton DM, et al. Altered epithelial lining fluid parameters in old normal individuals. J Gerontol. 1992;47(5):M171–6.PubMedCrossRef
25.
go back to reference Sharma G, Hanania NA, Shim YM. The aging immune system and its relationship to the development of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2009;6(7):573–80.PubMedCrossRef Sharma G, Hanania NA, Shim YM. The aging immune system and its relationship to the development of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2009;6(7):573–80.PubMedCrossRef
26.
go back to reference Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple co-morbid diseases. J Am Med Assoc. 2005;294(6):716–24.CrossRef Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple co-morbid diseases. J Am Med Assoc. 2005;294(6):716–24.CrossRef
27.
go back to reference Wilper AP, Woolhandler S, Lasser KE, et al. A national study of chronic disease prevalence and access to care in uninsured U.S. adults. Ann Intern Med. 2008;149(3):170–6.PubMedCrossRef Wilper AP, Woolhandler S, Lasser KE, et al. A national study of chronic disease prevalence and access to care in uninsured U.S. adults. Ann Intern Med. 2008;149(3):170–6.PubMedCrossRef
28.
go back to reference Boulet LP, Turcotte H, Turcot O, et al. Airway inflammation in asthma with incomplete reversibility of airflow obstruction. Respir Med. 2003;97:739–44.PubMedCrossRef Boulet LP, Turcotte H, Turcot O, et al. Airway inflammation in asthma with incomplete reversibility of airflow obstruction. Respir Med. 2003;97:739–44.PubMedCrossRef
29.
go back to reference Mannino DM, Hole D, Gillis C, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(3):627–43.PubMedCrossRef Mannino DM, Hole D, Gillis C, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(3):627–43.PubMedCrossRef
30.
go back to reference Fabbri L, Ferrari R. Chronic disease in the elderly: back to the future of internal medicine. Breathe. 2006;3:41–9. Fabbri L, Ferrari R. Chronic disease in the elderly: back to the future of internal medicine. Breathe. 2006;3:41–9.
31.
go back to reference Luppi F, Franco F, Beghé B, et al. Treatment of chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc. 2008;5:848–56.PubMedCrossRef Luppi F, Franco F, Beghé B, et al. Treatment of chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc. 2008;5:848–56.PubMedCrossRef
32.
go back to reference Agustí A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don’t know (but should). Proc Am Thorac Soc. 2007;4(7):522–5.PubMedCrossRef Agustí A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don’t know (but should). Proc Am Thorac Soc. 2007;4(7):522–5.PubMedCrossRef
33.
go back to reference Quinet P, Young CA, Héritier F. The use of dry powder inhaler devices by elderly patients suffering from chronic obstructive pulmonary disease. Ann Phys Rehabil Med. 2010;53(2):69–76.PubMedCrossRef Quinet P, Young CA, Héritier F. The use of dry powder inhaler devices by elderly patients suffering from chronic obstructive pulmonary disease. Ann Phys Rehabil Med. 2010;53(2):69–76.PubMedCrossRef
34.
go back to reference Janssens W, Vandenbrande P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31(1):78–83.PubMedCrossRef Janssens W, Vandenbrande P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31(1):78–83.PubMedCrossRef
35.
go back to reference Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418–22.PubMedCrossRef Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418–22.PubMedCrossRef
36.
go back to reference Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26.PubMedCrossRef Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26.PubMedCrossRef
37.
go back to reference Banning M. Older people and adherence with medication: a review of the literature. Int J Nurs Stud. 2008;45(10):1550–61.PubMedCrossRef Banning M. Older people and adherence with medication: a review of the literature. Int J Nurs Stud. 2008;45(10):1550–61.PubMedCrossRef
38.
go back to reference Goeman DP, Douglass JA. Optimal management of asthma in elderly patients: strategies to improve adherence to recommended interventions. Drugs Aging. 2007;24(5):381–94.PubMedCrossRef Goeman DP, Douglass JA. Optimal management of asthma in elderly patients: strategies to improve adherence to recommended interventions. Drugs Aging. 2007;24(5):381–94.PubMedCrossRef
39.
go back to reference Vozoris NT, Stanbrook MB. Smoking prevalence, behaviours, and cessation among individuals with COPD or asthma. Respir Med. 2011;105(3):477–84.PubMedCrossRef Vozoris NT, Stanbrook MB. Smoking prevalence, behaviours, and cessation among individuals with COPD or asthma. Respir Med. 2011;105(3):477–84.PubMedCrossRef
40.
go back to reference Gibson PG, Talbot PI, Toneguzzi RC. Self-management, autonomy, and quality of life in asthma. Chest. 1995;107(4):1003–8.PubMedCrossRef Gibson PG, Talbot PI, Toneguzzi RC. Self-management, autonomy, and quality of life in asthma. Chest. 1995;107(4):1003–8.PubMedCrossRef
41.
go back to reference Little P, Everitt H, Williamson I. Preferences of patients for patient centered approach to consultation in primary care: observational study. BMJ. 2001;322(7284):468–72.PubMedCrossRef Little P, Everitt H, Williamson I. Preferences of patients for patient centered approach to consultation in primary care: observational study. BMJ. 2001;322(7284):468–72.PubMedCrossRef
42.
43.
go back to reference GINA. Global strategy for asthma management and prevention: NHLBI/WHO workshop report. Bethesda (MD): Global Initiative for Asthma (GINA), National Heart, Lung and Blood Institute (NHLBI); 2006. GINA. Global strategy for asthma management and prevention: NHLBI/WHO workshop report. Bethesda (MD): Global Initiative for Asthma (GINA), National Heart, Lung and Blood Institute (NHLBI); 2006.
44.
go back to reference Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of COPD 2006 Update. Am J Respir Crit Care Med. 2007;176:532–55.PubMedCrossRef Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of COPD 2006 Update. Am J Respir Crit Care Med. 2007;176:532–55.PubMedCrossRef
45.
go back to reference Gibson PG, Simpson JS. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax. 2009;64:728–35.PubMedCrossRef Gibson PG, Simpson JS. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax. 2009;64:728–35.PubMedCrossRef
46.
go back to reference Snider GL. Distinguishing among asthma, chronic bronchitis, and emphysema. Chest. 1985;87(1 Suppl):35S–9S.PubMed Snider GL. Distinguishing among asthma, chronic bronchitis, and emphysema. Chest. 1985;87(1 Suppl):35S–9S.PubMed
47.
go back to reference American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152:s77–121. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152:s77–121.
48.
go back to reference Soriano JB, Davis KJ, Coleman B, et al. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest. 2003;124:474–81.PubMedCrossRef Soriano JB, Davis KJ, Coleman B, et al. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest. 2003;124:474–81.PubMedCrossRef
49.
go back to reference Marsh SE, Travers J, Weatherall M, et al. Proportional classifications of COPD phenotypes. Thorax. 2008;63:761–7.PubMedCrossRef Marsh SE, Travers J, Weatherall M, et al. Proportional classifications of COPD phenotypes. Thorax. 2008;63:761–7.PubMedCrossRef
50.
go back to reference Weatherall M, Travers J, Shirtcliffe PM, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J. 2009;34(4):812–8.PubMedCrossRef Weatherall M, Travers J, Shirtcliffe PM, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J. 2009;34(4):812–8.PubMedCrossRef
51.
go back to reference Vonk JM, Jongepier H, Panhuysen CIM, et al. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax. 2003;58:322–7.PubMedCrossRef Vonk JM, Jongepier H, Panhuysen CIM, et al. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax. 2003;58:322–7.PubMedCrossRef
52.
go back to reference Calverley PM, Burge PS, Spencer S, et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003;58(8):659–64.PubMedCrossRef Calverley PM, Burge PS, Spencer S, et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003;58(8):659–64.PubMedCrossRef
53.
go back to reference Reid DW, Soltani A, Johns DP, et al. Bronchodilator reversibility in Australian adults with chronic obstructive pulmonary disease. Intern Med J. 2003;33(12):572–7.PubMedCrossRef Reid DW, Soltani A, Johns DP, et al. Bronchodilator reversibility in Australian adults with chronic obstructive pulmonary disease. Intern Med J. 2003;33(12):572–7.PubMedCrossRef
54.
go back to reference Simpson JL, Scott R, Boyle M, et al. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006;11:54–61.PubMedCrossRef Simpson JL, Scott R, Boyle M, et al. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006;11:54–61.PubMedCrossRef
55.
go back to reference Gorska K, Krenke R, Korczynski P, et al. Eosinophilic airway inflammation in chronic obstructive pulmonary disease and asthma. J Physiol Pharmacol. 2008;59(Suppl 6):261–70.PubMed Gorska K, Krenke R, Korczynski P, et al. Eosinophilic airway inflammation in chronic obstructive pulmonary disease and asthma. J Physiol Pharmacol. 2008;59(Suppl 6):261–70.PubMed
56.
go back to reference Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29(5):906–13.PubMedCrossRef Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29(5):906–13.PubMedCrossRef
57.
go back to reference Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008;177(2):148–55.PubMedCrossRef Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008;177(2):148–55.PubMedCrossRef
58.
59.
go back to reference D’silva L, Cook RJ, Allen CJ, et al. Changing pattern of sputum cell counts during successive exacerbations of airway disease. Respir Med. 2007;101:2217–20.PubMedCrossRef D’silva L, Cook RJ, Allen CJ, et al. Changing pattern of sputum cell counts during successive exacerbations of airway disease. Respir Med. 2007;101:2217–20.PubMedCrossRef
60.
go back to reference Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Bethesda (MD): Global Initiative for Chronic Obstructive Lung Disease; 2011. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Bethesda (MD): Global Initiative for Chronic Obstructive Lung Disease; 2011.
62.
go back to reference Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297–303.PubMedCrossRef Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297–303.PubMedCrossRef
63.
go back to reference Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax. 2005;60(12):992–7.PubMedCrossRef Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax. 2005;60(12):992–7.PubMedCrossRef
64.
go back to reference Gibson PG, Powell H, Coughlin J, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database of Systematic Reviews. 2003;(3):CD001117. Gibson PG, Powell H, Coughlin J, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database of Systematic Reviews. 2003;(3):CD001117.
65.
go back to reference Effing TW, Monninkhof EM, van der Valk PDLPM, et al. Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2007;(4):CD002990. Effing TW, Monninkhof EM, van der Valk PDLPM, et al. Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2007;(4):CD002990.
66.
go back to reference Willemse BW, Postma DS, Timens W, et al. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J. 2004;23(3):464–76.PubMedCrossRef Willemse BW, Postma DS, Timens W, et al. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J. 2004;23(3):464–76.PubMedCrossRef
67.
go back to reference Franceschi C, Bonafè M. Centenarians as a model for healthy aging. Biochem Soc Trans. 2003;31(2):457–61.PubMedCrossRef Franceschi C, Bonafè M. Centenarians as a model for healthy aging. Biochem Soc Trans. 2003;31(2):457–61.PubMedCrossRef
68.
go back to reference Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet. 2007;1(370):797–9.CrossRef Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet. 2007;1(370):797–9.CrossRef
69.
go back to reference Agustí AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:347–60.PubMedCrossRef Agustí AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:347–60.PubMedCrossRef
70.
go back to reference Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574–80.PubMedCrossRef Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574–80.PubMedCrossRef
71.
go back to reference Yokoyama A, Kohno N, Fujino S, et al. Circulating interleukin-6 levels in patients with bronchial asthma. Am J Respir Crit Care Med. 1995;151(5):1354–8.PubMedCrossRef Yokoyama A, Kohno N, Fujino S, et al. Circulating interleukin-6 levels in patients with bronchial asthma. Am J Respir Crit Care Med. 1995;151(5):1354–8.PubMedCrossRef
72.
go back to reference Takemura M, Matsumoto H, Niimi A, et al. High sensitivity C-reactive protein in asthma. Eur Respir J. 2006;27(5):908–12.PubMed Takemura M, Matsumoto H, Niimi A, et al. High sensitivity C-reactive protein in asthma. Eur Respir J. 2006;27(5):908–12.PubMed
73.
go back to reference Higashimoto Y, Yamagata Y, Taya S, et al. Systemic inflammation in chronic obstructive pulmonary disease and asthma: similarities and differences. Respirology. 2008;13:128–33.PubMed Higashimoto Y, Yamagata Y, Taya S, et al. Systemic inflammation in chronic obstructive pulmonary disease and asthma: similarities and differences. Respirology. 2008;13:128–33.PubMed
74.
go back to reference Pauwels R, Calverley P, Buist AS, et al. COPD exacerbations: the importance of a standard definition. Resp Med. 2004;98:99–107.CrossRef Pauwels R, Calverley P, Buist AS, et al. COPD exacerbations: the importance of a standard definition. Resp Med. 2004;98:99–107.CrossRef
75.
go back to reference Hurst JR, Wedzicha JA. The biology of a chronic obstructive pulmonary disease exacerbation. Clin Chest Med. 2007;28(3):525–36.PubMedCrossRef Hurst JR, Wedzicha JA. The biology of a chronic obstructive pulmonary disease exacerbation. Clin Chest Med. 2007;28(3):525–36.PubMedCrossRef
76.
go back to reference Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–85.PubMedCrossRef Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–85.PubMedCrossRef
77.
go back to reference Smith DJ, Yerkovich ST, Towers MA, et al. Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J. 2011;37(3):516–22.PubMedCrossRef Smith DJ, Yerkovich ST, Towers MA, et al. Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J. 2011;37(3):516–22.PubMedCrossRef
78.
go back to reference Lopez-Campos J, Arellano E, Calero C, et al. Determination of inflammatory biomarkers in patients with COPD: a comparison of different assays. BMC Med Res Methodol. 2012;12(1):40.PubMedCrossRef Lopez-Campos J, Arellano E, Calero C, et al. Determination of inflammatory biomarkers in patients with COPD: a comparison of different assays. BMC Med Res Methodol. 2012;12(1):40.PubMedCrossRef
79.
go back to reference Bozinovski S, Uddin M, Vlahos R, et al. Serum amyloid A opposes lipoxin A to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci USA. 2012;109(3):935–40.PubMedCrossRef Bozinovski S, Uddin M, Vlahos R, et al. Serum amyloid A opposes lipoxin A to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci USA. 2012;109(3):935–40.PubMedCrossRef
80.
go back to reference Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;23:23. Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;23:23.
81.
go back to reference Lomas DA, Silverman EK, Edwards LD, et al. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax. 2008;63(12):1058–63. Lomas DA, Silverman EK, Edwards LD, et al. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax. 2008;63(12):1058–63.
82.
go back to reference Verrills NM, Irwin JA, He XY, et al. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183(12):1633–43.PubMedCrossRef Verrills NM, Irwin JA, He XY, et al. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183(12):1633–43.PubMedCrossRef
83.
go back to reference American Healthways, Johns Hopkins. Standard outcome metrics and evaluation outcome methodology for disease management programmes. Second Annual Disease Management Outcomes Summit; 2002 Nov 7–10; Palm Desert, CA. Franklin, TN: American Healthways; 2002. American Healthways, Johns Hopkins. Standard outcome metrics and evaluation outcome methodology for disease management programmes. Second Annual Disease Management Outcomes Summit; 2002 Nov 7–10; Palm Desert, CA. Franklin, TN: American Healthways; 2002.
84.
go back to reference Vitry AI, Zhang Y. Quality of Australian clinical guidelines and relevance to the care of older people with multiple comorbid conditions. Med J Aust. 2008;189(7):360–5.PubMed Vitry AI, Zhang Y. Quality of Australian clinical guidelines and relevance to the care of older people with multiple comorbid conditions. Med J Aust. 2008;189(7):360–5.PubMed
85.
go back to reference Craig BM, Kraus CK, Chewning BA, et al. Quality of care for older adults with chronic obstructive pulmonary disease and asthma based on comparisons to practice guidelines and smoking status. BMC Health Serv Res. 2008;8:1–9. Craig BM, Kraus CK, Chewning BA, et al. Quality of care for older adults with chronic obstructive pulmonary disease and asthma based on comparisons to practice guidelines and smoking status. BMC Health Serv Res. 2008;8:1–9.
86.
go back to reference Costantino G, Rusconi AM, Duca PG, et al. Eligibility criteria in heart failure randomized controlled trials: a gap between evidence and clinical practice. Intern Emerg Med. 2008;4(2):117–22.PubMedCrossRef Costantino G, Rusconi AM, Duca PG, et al. Eligibility criteria in heart failure randomized controlled trials: a gap between evidence and clinical practice. Intern Emerg Med. 2008;4(2):117–22.PubMedCrossRef
87.
go back to reference Travers J, Marsh S, Williams M, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax. 2007;62(3):219–23.PubMedCrossRef Travers J, Marsh S, Williams M, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax. 2007;62(3):219–23.PubMedCrossRef
88.
go back to reference Travers J, Marsh S, Caldwell B, et al. External validity of randomized controlled trials in COPD. Respir Med. 2007;101(6):1313–20.PubMedCrossRef Travers J, Marsh S, Caldwell B, et al. External validity of randomized controlled trials in COPD. Respir Med. 2007;101(6):1313–20.PubMedCrossRef
89.
go back to reference Ware JH, Hamel MB. Pragmatic trials—guides to better patient care? N Engl J Med. 2011;364(18):1685–7.PubMedCrossRef Ware JH, Hamel MB. Pragmatic trials—guides to better patient care? N Engl J Med. 2011;364(18):1685–7.PubMedCrossRef
90.
go back to reference Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374(9696):1171–8.PubMedCrossRef Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374(9696):1171–8.PubMedCrossRef
91.
go back to reference Gibson PG. Using fractional exhaled nitric oxide to guide asthma therapy: design and methodological issues for ASthma TReatment ALgorithm studies. Clin Exp Allergy. 2009;39(4):478–90.PubMedCrossRef Gibson PG. Using fractional exhaled nitric oxide to guide asthma therapy: design and methodological issues for ASthma TReatment ALgorithm studies. Clin Exp Allergy. 2009;39(4):478–90.PubMedCrossRef
92.
go back to reference Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet. 2011;378(9795):983–90.PubMedCrossRef Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet. 2011;378(9795):983–90.PubMedCrossRef
93.
go back to reference Hunter DJ, Fairfield G. Disease management. Br Med J. 1997;315(7099):50–3.CrossRef Hunter DJ, Fairfield G. Disease management. Br Med J. 1997;315(7099):50–3.CrossRef
94.
go back to reference Hunter DJ. Disease management: has it a future? It has a compelling logic, but needs to be tested in practice. Br Med J. 2000;320(7234):530.CrossRef Hunter DJ. Disease management: has it a future? It has a compelling logic, but needs to be tested in practice. Br Med J. 2000;320(7234):530.CrossRef
95.
go back to reference Solomon D, Brown SA, Brummel-Smith K, et al. Best paper of the 1980 s: National Institutes of Health Consensus Development Conference Statement: geriatric assessment methods for clinical decision-making. 1988. J Am Geriatr Soc. 2003;51(10):1490–4.PubMedCrossRef Solomon D, Brown SA, Brummel-Smith K, et al. Best paper of the 1980 s: National Institutes of Health Consensus Development Conference Statement: geriatric assessment methods for clinical decision-making. 1988. J Am Geriatr Soc. 2003;51(10):1490–4.PubMedCrossRef
96.
go back to reference Vliek S, Melis RJ, Faes M, et al. Single versus multicomponent intervention in frail elderly: simplicity or complexity as precondition for success? J Nutr Health Aging. 2008;12(5):319–22.PubMedCrossRef Vliek S, Melis RJ, Faes M, et al. Single versus multicomponent intervention in frail elderly: simplicity or complexity as precondition for success? J Nutr Health Aging. 2008;12(5):319–22.PubMedCrossRef
97.
go back to reference Stuck AE, Siu AL, Wieland GD, et al. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet. 1993;342:1032–6.PubMedCrossRef Stuck AE, Siu AL, Wieland GD, et al. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet. 1993;342:1032–6.PubMedCrossRef
98.
go back to reference McDonald VM, Higgins I, Wood LG, et al. Multidimensional assessment and individualised management of obstructive airway diseases (OAD) in older adults. Respirology. 2011;16:13.CrossRef McDonald VM, Higgins I, Wood LG, et al. Multidimensional assessment and individualised management of obstructive airway diseases (OAD) in older adults. Respirology. 2011;16:13.CrossRef
99.
go back to reference Koff PB, Jones RH, Cashman JM, et al. Proactive integrated care improves quality of life in patients with COPD. Eur Respir J. 2009;33(5):1031–8.PubMedCrossRef Koff PB, Jones RH, Cashman JM, et al. Proactive integrated care improves quality of life in patients with COPD. Eur Respir J. 2009;33(5):1031–8.PubMedCrossRef
100.
go back to reference Rice KL, Dewan N, Bloomfield HE, et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2010;182(7):890–6.PubMedCrossRef Rice KL, Dewan N, Bloomfield HE, et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2010;182(7):890–6.PubMedCrossRef
101.
102.
go back to reference McDonald VM, Higgins I, Simpson JL, et al. The importance of clinical management problems in older people with COPD and asthma: do patients and physicians agree? Prim Care Respir J. 2011;20(4):389–95.PubMedCrossRef McDonald VM, Higgins I, Simpson JL, et al. The importance of clinical management problems in older people with COPD and asthma: do patients and physicians agree? Prim Care Respir J. 2011;20(4):389–95.PubMedCrossRef
103.
go back to reference National Ageing Research Institute. What is person-centred health care? A literature review. Melbourne: Ageing and Complex Care, Continuing Care, Integrated Care, Wellbeing, Integrated Care and Ageing, Department of Health; 2006. National Ageing Research Institute. What is person-centred health care? A literature review. Melbourne: Ageing and Complex Care, Continuing Care, Integrated Care, Wellbeing, Integrated Care and Ageing, Department of Health; 2006.
104.
go back to reference Bauman AE, Fardy HJ, Harris PG. Getting it right: why bother with patient-centered care? Med J Aust. 2003;179(5):253–6.PubMed Bauman AE, Fardy HJ, Harris PG. Getting it right: why bother with patient-centered care? Med J Aust. 2003;179(5):253–6.PubMed
105.
go back to reference Wilson SR, Strub P, Buist AS, et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med. 2010;181(6):566–77.PubMedCrossRef Wilson SR, Strub P, Buist AS, et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med. 2010;181(6):566–77.PubMedCrossRef
106.
go back to reference Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360(10):985–93.PubMedCrossRef Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360(10):985–93.PubMedCrossRef
107.
go back to reference Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;30:1715–21.CrossRef Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;30:1715–21.CrossRef
108.
go back to reference Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J. 2006;27:483–94.PubMedCrossRef Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J. 2006;27:483–94.PubMedCrossRef
109.
go back to reference Petsky HL, Kynaston JA, Turner C, et al. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database of Systematic Reviews. 2007; (2): CD005603. Petsky HL, Kynaston JA, Turner C, et al. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database of Systematic Reviews. 2007; (2): CD005603.
110.
go back to reference Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–98.PubMedCrossRef Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–98.PubMedCrossRef
111.
go back to reference Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178(11):1139–47.PubMedCrossRef Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178(11):1139–47.PubMedCrossRef
112.
go back to reference He ZY, Ou LM, Zhang JQ, et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration. 2010;80(6):445–52.PubMedCrossRef He ZY, Ou LM, Zhang JQ, et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration. 2010;80(6):445–52.PubMedCrossRef
113.
114.
go back to reference Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749–56.PubMedCrossRef Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749–56.PubMedCrossRef
115.
go back to reference Tateda K, Standiford TJ, Pechere JC, et al. Regulatory effects of macrolides on bacterial virulence: potential role as quorum-sensing inhibitors. Curr Pharm Des. 2004;10:3055–65.PubMedCrossRef Tateda K, Standiford TJ, Pechere JC, et al. Regulatory effects of macrolides on bacterial virulence: potential role as quorum-sensing inhibitors. Curr Pharm Des. 2004;10:3055–65.PubMedCrossRef
116.
go back to reference López-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opin Pharmacol. 2008;8:286–91.PubMedCrossRef López-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opin Pharmacol. 2008;8:286–91.PubMedCrossRef
117.
go back to reference Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)—can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006;97(2A):33A–41A.PubMedCrossRef Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)—can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006;97(2A):33A–41A.PubMedCrossRef
118.
go back to reference Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20–8.PubMedCrossRef Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20–8.PubMedCrossRef
119.
go back to reference Lee T-M, Lin M-S, Chang N-C. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol. 2008;101(4):530–5.PubMedCrossRef Lee T-M, Lin M-S, Chang N-C. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol. 2008;101(4):530–5.PubMedCrossRef
120.
go back to reference Suissa S. Co-morbidity in COPD: the effects of cardiovascular drug therapies. Respiration. 2010;80(1):3–7.PubMedCrossRef Suissa S. Co-morbidity in COPD: the effects of cardiovascular drug therapies. Respiration. 2010;80(1):3–7.PubMedCrossRef
121.
go back to reference Lee T-M, Chen C–C, Shen H-N, et al. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci. 2009;116(6):497–505.PubMedCrossRef Lee T-M, Chen C–C, Shen H-N, et al. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci. 2009;116(6):497–505.PubMedCrossRef
122.
go back to reference Blamoun AI, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract. 2008;62(9):1373–8.PubMedCrossRef Blamoun AI, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract. 2008;62(9):1373–8.PubMedCrossRef
123.
go back to reference Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest. 2007;132(6):1764–71.PubMedCrossRef Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest. 2007;132(6):1764–71.PubMedCrossRef
124.
go back to reference Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47(12):2554–60.PubMedCrossRef Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47(12):2554–60.PubMedCrossRef
125.
go back to reference Frost FJ, Petersen H, Tollestrup K, et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007;131(4):1006–12.PubMedCrossRef Frost FJ, Petersen H, Tollestrup K, et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007;131(4):1006–12.PubMedCrossRef
126.
go back to reference Ishida W, Kajiwara T, Taneichi H, et al. Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan. Tohoku J Exp Med. 2007;212(3):265–73.PubMedCrossRef Ishida W, Kajiwara T, Taneichi H, et al. Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan. Tohoku J Exp Med. 2007;212(3):265–73.PubMedCrossRef
127.
go back to reference van Gestel YRBM, Hoeks SE, Sin DD, et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol. 2008;102(2):192–6.PubMedCrossRef van Gestel YRBM, Hoeks SE, Sin DD, et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol. 2008;102(2):192–6.PubMedCrossRef
128.
go back to reference Ulrik CS, von Linstow ML, Nepper-Christensen S, Porsbjerg C, Backer V. Chronic mucus hypersecretion: a marker of asthma in young adults. Respir Med. 2005;99:1576–82. Ulrik CS, von Linstow ML, Nepper-Christensen S, Porsbjerg C, Backer V. Chronic mucus hypersecretion: a marker of asthma in young adults. Respir Med. 2005;99:1576–82.
129.
go back to reference Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med. 2001;163:1256–76.PubMedCrossRef Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med. 2001;163:1256–76.PubMedCrossRef
130.
go back to reference Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care. 2007;52:1176–93.PubMed Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care. 2007;52:1176–93.PubMed
131.
go back to reference Henke MO, Shah SA, Rubin BK. The role of airway secretions in COPD—clinical applications. COPD. 2005;2:377–90.PubMedCrossRef Henke MO, Shah SA, Rubin BK. The role of airway secretions in COPD—clinical applications. COPD. 2005;2:377–90.PubMedCrossRef
132.
go back to reference Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354:229–40.PubMedCrossRef Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354:229–40.PubMedCrossRef
133.
go back to reference Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database of Systematic Reviews. 2009;(2): CD001506. Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database of Systematic Reviews. 2009;(2): CD001506.
134.
go back to reference Pavia D, Thomson ML, Clarke SW. Enhanced clearance of secretions from the human lung after the administration of hypertonic saline aerosol. Am J Respir Crit Care Med. 1978;117:199–203. Pavia D, Thomson ML, Clarke SW. Enhanced clearance of secretions from the human lung after the administration of hypertonic saline aerosol. Am J Respir Crit Care Med. 1978;117:199–203.
135.
go back to reference Clarke SW, Lopez-Vidriero MT, Pavia D, et al. The effect of sodium 2-mercapto-ethane sulphonate and hypertonic saline aerosols on bronchial clearance in chronic bronchitis. Br J Clin Pharmacol. 1979;7:39–44.PubMedCrossRef Clarke SW, Lopez-Vidriero MT, Pavia D, et al. The effect of sodium 2-mercapto-ethane sulphonate and hypertonic saline aerosols on bronchial clearance in chronic bronchitis. Br J Clin Pharmacol. 1979;7:39–44.PubMedCrossRef
136.
go back to reference Daviskas E, Anderson SD, Young IH. Inhaled mannitol changes the sputum properties in asthmatics with mucus hypersecretion. Respirology. 2007;12(5):683–91.PubMedCrossRef Daviskas E, Anderson SD, Young IH. Inhaled mannitol changes the sputum properties in asthmatics with mucus hypersecretion. Respirology. 2007;12(5):683–91.PubMedCrossRef
137.
go back to reference Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database of Systematic Reviews. 2006;(2): CD002996. Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database of Systematic Reviews. 2006;(2): CD002996.
138.
go back to reference Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(12):1259–65.PubMedCrossRef Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(12):1259–65.PubMedCrossRef
139.
go back to reference Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127(6):1952–9.PubMedCrossRef Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127(6):1952–9.PubMedCrossRef
140.
go back to reference Shamsham F, Mitchell J. Essentials of the diagnosis of heart failure. Fam Physician. 2000;61:1319–28. Shamsham F, Mitchell J. Essentials of the diagnosis of heart failure. Fam Physician. 2000;61:1319–28.
141.
go back to reference Roth SM, Metter EJ, Ling S, et al. Inflammatory factors in age-related muscle wasting. Curr Opin Rheumatol. 2006;18:625–30.PubMedCrossRef Roth SM, Metter EJ, Ling S, et al. Inflammatory factors in age-related muscle wasting. Curr Opin Rheumatol. 2006;18:625–30.PubMedCrossRef
142.
go back to reference Schols AM, Soeters PB, Dingemans AM, et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis. 1993;147:1151–6.PubMedCrossRef Schols AM, Soeters PB, Dingemans AM, et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis. 1993;147:1151–6.PubMedCrossRef
143.
go back to reference Mostert R, Goris A, Weling-Scheepers C, et al. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. Respir Med. 2000;94(4):859–67.PubMedCrossRef Mostert R, Goris A, Weling-Scheepers C, et al. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. Respir Med. 2000;94(4):859–67.PubMedCrossRef
144.
go back to reference Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002;288(14):1723–7.PubMedCrossRef Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002;288(14):1723–7.PubMedCrossRef
145.
go back to reference Oreopoulos A, Kalantar-Zadeh K, Sharma AM, et al. The obesity paradox in the elderly: potential mechanisms and clinical implications. Clin Geriatr Med. 2009;24(4):643–59.CrossRef Oreopoulos A, Kalantar-Zadeh K, Sharma AM, et al. The obesity paradox in the elderly: potential mechanisms and clinical implications. Clin Geriatr Med. 2009;24(4):643–59.CrossRef
146.
go back to reference Losonczy KG, Harris TB, Cornoni-Huntley J, et al. Does weight loss from middle age to old age explain the inverse weight mortality relation in old age? Am J Epidemiol. 1995;141(4):312–21.PubMedCrossRef Losonczy KG, Harris TB, Cornoni-Huntley J, et al. Does weight loss from middle age to old age explain the inverse weight mortality relation in old age? Am J Epidemiol. 1995;141(4):312–21.PubMedCrossRef
147.
go back to reference Grabowski DC, Ellis JE. High body mass index does not predict mortality in older people: analysis of the Longitudinal Study of Aging. J Am Geriatr Soc. 2001;49(7):968–79.PubMedCrossRef Grabowski DC, Ellis JE. High body mass index does not predict mortality in older people: analysis of the Longitudinal Study of Aging. J Am Geriatr Soc. 2001;49(7):968–79.PubMedCrossRef
148.
go back to reference Villareal DT, Apovian CM, Kushner RF, et al. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Am J Clin Nutr. 2005;82(5):923–34.PubMed Villareal DT, Apovian CM, Kushner RF, et al. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Am J Clin Nutr. 2005;82(5):923–34.PubMed
149.
go back to reference Chailleux E, Laaban JP, Veale D. Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy: data from the ANTADIR observatory. Chest. 2003;123(5):1460–6.PubMedCrossRef Chailleux E, Laaban JP, Veale D. Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy: data from the ANTADIR observatory. Chest. 2003;123(5):1460–6.PubMedCrossRef
150.
go back to reference Landbo C, Prescott E, Lange PT, et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:1856–61.PubMedCrossRef Landbo C, Prescott E, Lange PT, et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:1856–61.PubMedCrossRef
151.
go back to reference Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–12.PubMedCrossRef Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–12.PubMedCrossRef
152.
go back to reference Schols AM, Slangen J, Volovics L, et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1791–7.PubMedCrossRef Schols AM, Slangen J, Volovics L, et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1791–7.PubMedCrossRef
154.
go back to reference Flicker L, McCaul KA, Hankey GJ, et al. Body mass index and survival in men and women aged 70 to 75. J Am Geriatr Soc. 2010;58(2):234–41.PubMedCrossRef Flicker L, McCaul KA, Hankey GJ, et al. Body mass index and survival in men and women aged 70 to 75. J Am Geriatr Soc. 2010;58(2):234–41.PubMedCrossRef
155.
go back to reference Franssen FME, O’Donnell DE, Goossens GH, et al. Obesity and the lung: 5. Obesity and COPD. Thorax. 2008;63:1110–7.PubMedCrossRef Franssen FME, O’Donnell DE, Goossens GH, et al. Obesity and the lung: 5. Obesity and COPD. Thorax. 2008;63:1110–7.PubMedCrossRef
156.
go back to reference Steuten LM, Creutzberg EC, Vrijhoef HJ, et al. COPD as a multicomponent disease: inventory of dyspnoea, underweight, obesity and fat free mass depletion in primary care. Prim Care Respir J. 2006;15:84–91.PubMedCrossRef Steuten LM, Creutzberg EC, Vrijhoef HJ, et al. COPD as a multicomponent disease: inventory of dyspnoea, underweight, obesity and fat free mass depletion in primary care. Prim Care Respir J. 2006;15:84–91.PubMedCrossRef
157.
go back to reference Eisner MD, Blanc PD, Sidney S, et al. Body composition and functional limitation in COPD. Respir Res. 2007;8:7.PubMedCrossRef Eisner MD, Blanc PD, Sidney S, et al. Body composition and functional limitation in COPD. Respir Res. 2007;8:7.PubMedCrossRef
158.
go back to reference Aronson D, Bartha P, Zinder O, et al. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord. 2004;28:674–9.PubMedCrossRef Aronson D, Bartha P, Zinder O, et al. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord. 2004;28:674–9.PubMedCrossRef
159.
go back to reference Florez H, Castillo-Florez S, Mendez A, et al. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract. 2006;71:92–100.PubMedCrossRef Florez H, Castillo-Florez S, Mendez A, et al. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract. 2006;71:92–100.PubMedCrossRef
160.
go back to reference Vandenbergh E, Van de Woestijne KP, Gyselen A. Weight changes in the terminal stages of chronic obstructive pulmonary disease. Relation to respiratory function and prognosis. Am Rev Respir Dis. 1967;95:556–66.PubMed Vandenbergh E, Van de Woestijne KP, Gyselen A. Weight changes in the terminal stages of chronic obstructive pulmonary disease. Relation to respiratory function and prognosis. Am Rev Respir Dis. 1967;95:556–66.PubMed
161.
go back to reference Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178:322–3.CrossRef Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178:322–3.CrossRef
162.
go back to reference Peters-Golden M, Swern A, Bird SS, et al. Influence of body mass index on the response to asthma controller agents. Eur Respir J. 2006;27(3):495–503.PubMedCrossRef Peters-Golden M, Swern A, Bird SS, et al. Influence of body mass index on the response to asthma controller agents. Eur Respir J. 2006;27(3):495–503.PubMedCrossRef
163.
go back to reference Wood LG, Gibson PG. Dietary factors lead to innate immune activation in asthma. Pharmacol Ther. 2009;123(1):37–53.PubMedCrossRef Wood LG, Gibson PG. Dietary factors lead to innate immune activation in asthma. Pharmacol Ther. 2009;123(1):37–53.PubMedCrossRef
164.
165.
go back to reference Foley DJ, Monjan AA, Brown SL, et al. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep. 1995;18(6):425–32.PubMed Foley DJ, Monjan AA, Brown SL, et al. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep. 1995;18(6):425–32.PubMed
166.
167.
go back to reference Zamarrón C, García Paz V, Morete E, et al. Association of chronic obstructive pulmonary disease and obstructive sleep apnea consequences. Int J Chron Obstruct Pulmon Dis. 2008;3(4):671–82. Zamarrón C, García Paz V, Morete E, et al. Association of chronic obstructive pulmonary disease and obstructive sleep apnea consequences. Int J Chron Obstruct Pulmon Dis. 2008;3(4):671–82.
168.
go back to reference Jorgensen NR, Schwarz P, Holme I, et al. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease—a cross sectional study. Respir Med. 2007;101:177–85.PubMedCrossRef Jorgensen NR, Schwarz P, Holme I, et al. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease—a cross sectional study. Respir Med. 2007;101:177–85.PubMedCrossRef
169.
go back to reference Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med. 2001;345(13):941–7.PubMedCrossRef Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med. 2001;345(13):941–7.PubMedCrossRef
170.
go back to reference Ip M, Lam K, Yam L, et al. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest. 1994;105(6):1722–7.PubMedCrossRef Ip M, Lam K, Yam L, et al. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest. 1994;105(6):1722–7.PubMedCrossRef
171.
go back to reference Cote C, Zilberberg MD, Mody SH, et al. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J. 2007;29(5):923–9.PubMedCrossRef Cote C, Zilberberg MD, Mody SH, et al. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J. 2007;29(5):923–9.PubMedCrossRef
172.
go back to reference Kvaal K, Macijauskiene J, Engedal K, et al. High prevalence of anxiety symptoms in hospitalized geriatric patients. Int J Geriatr Psychiatry. 2001;16(7):690–3.PubMedCrossRef Kvaal K, Macijauskiene J, Engedal K, et al. High prevalence of anxiety symptoms in hospitalized geriatric patients. Int J Geriatr Psychiatry. 2001;16(7):690–3.PubMedCrossRef
173.
go back to reference Cafarella PA, Effing TW, Usmani ZA, et al. Treatments for anxiety and depression in patients with chronic obstructive pulmonary disease: a literature review. Respirology. 2012;17(4):627–38.PubMedCrossRef Cafarella PA, Effing TW, Usmani ZA, et al. Treatments for anxiety and depression in patients with chronic obstructive pulmonary disease: a literature review. Respirology. 2012;17(4):627–38.PubMedCrossRef
174.
go back to reference Yohannes AM, Baldwin RC, Connolly MJ. Prevalence of sub-threshold depression in elderly patients with chronic obstructive pulmonary disease. Int J Geriatr Psychiatry. 2003;18(5):412–6.PubMedCrossRef Yohannes AM, Baldwin RC, Connolly MJ. Prevalence of sub-threshold depression in elderly patients with chronic obstructive pulmonary disease. Int J Geriatr Psychiatry. 2003;18(5):412–6.PubMedCrossRef
175.
go back to reference Kim HF, Kunik ME, Molinari VA, et al. Functional impairment in COPD patients: the impact of anxiety and depression. Psychosomatics. 2000;41(6):465–71.PubMedCrossRef Kim HF, Kunik ME, Molinari VA, et al. Functional impairment in COPD patients: the impact of anxiety and depression. Psychosomatics. 2000;41(6):465–71.PubMedCrossRef
176.
go back to reference Kunik ME, Roundy K, Veazey C, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest. 2005;127(4):1205–11.PubMedCrossRef Kunik ME, Roundy K, Veazey C, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest. 2005;127(4):1205–11.PubMedCrossRef
177.
go back to reference DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101–7.PubMedCrossRef DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101–7.PubMedCrossRef
178.
go back to reference Yohannes AM, Baldwin RC, Connolly MJ. Predictors of 1-year mortality in patients discharged from hospital following acute exacerbation of chronic obstructive pulmonary disease. Age Ageing. 2005;34(5):491–6.PubMedCrossRef Yohannes AM, Baldwin RC, Connolly MJ. Predictors of 1-year mortality in patients discharged from hospital following acute exacerbation of chronic obstructive pulmonary disease. Age Ageing. 2005;34(5):491–6.PubMedCrossRef
179.
go back to reference Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest. 2008;134(4 Suppl):43S–56S.PubMedCrossRef Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest. 2008;134(4 Suppl):43S–56S.PubMedCrossRef
180.
go back to reference Rennard SI, Farmer SG. Exacerbations and progression of disease in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1(2):88–92.PubMedCrossRef Rennard SI, Farmer SG. Exacerbations and progression of disease in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1(2):88–92.PubMedCrossRef
181.
go back to reference Hurst JR, Donaldson GC, Quint JK, et al. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179(5):369–74.PubMedCrossRef Hurst JR, Donaldson GC, Quint JK, et al. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179(5):369–74.PubMedCrossRef
182.
go back to reference Bai TR, Vonk JM, Postma DS, et al. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J. 2007;30(3):452–6.PubMedCrossRef Bai TR, Vonk JM, Postma DS, et al. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J. 2007;30(3):452–6.PubMedCrossRef
183.
go back to reference Clarke SW. Management of mucus hypersecretion. Eur Resp J. 1987;136–44:153. Clarke SW. Management of mucus hypersecretion. Eur Resp J. 1987;136–44:153.
184.
go back to reference Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med. 1996;153:1530–5.PubMedCrossRef Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med. 1996;153:1530–5.PubMedCrossRef
185.
go back to reference Rogers DF. Airway mucus hypersecretion in asthma: an undervalued pathology? Curr Opin Pharmacol. 2004;4(3):241–50.PubMedCrossRef Rogers DF. Airway mucus hypersecretion in asthma: an undervalued pathology? Curr Opin Pharmacol. 2004;4(3):241–50.PubMedCrossRef
186.
go back to reference Roche N. Activity limitation: a major consequence of dyspnoea in COPD. Eur Respir Rev. 2009;18(112):54–7.PubMedCrossRef Roche N. Activity limitation: a major consequence of dyspnoea in COPD. Eur Respir Rev. 2009;18(112):54–7.PubMedCrossRef
187.
go back to reference Pitta F, Troosters T, Spruit MA, et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171(9):972–7.PubMedCrossRef Pitta F, Troosters T, Spruit MA, et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171(9):972–7.PubMedCrossRef
188.
go back to reference Schönhofer B, Ardes P, Geibel M, et al. Evaluation of a movement detector to measure daily activity in patients with chronic lung disease. Eur Respir J. 1997;10(12):2814–9.PubMedCrossRef Schönhofer B, Ardes P, Geibel M, et al. Evaluation of a movement detector to measure daily activity in patients with chronic lung disease. Eur Respir J. 1997;10(12):2814–9.PubMedCrossRef
190.
go back to reference Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med. 2007;175(5):458–63.PubMedCrossRef Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med. 2007;175(5):458–63.PubMedCrossRef
191.
go back to reference Strine TW, Balluz LS, Ford ES. The associations between smoking, physical inactivity, obesity, and asthma severity in the general US population. J Asthma. 2008;44(8):651–8.CrossRef Strine TW, Balluz LS, Ford ES. The associations between smoking, physical inactivity, obesity, and asthma severity in the general US population. J Asthma. 2008;44(8):651–8.CrossRef
192.
go back to reference Sherriff A, Maitra A, Ness AR, et al. Association of duration of television viewing in early childhood with the subsequent development of asthma. Thorax. 2009;64(4):321–5.PubMedCrossRef Sherriff A, Maitra A, Ness AR, et al. Association of duration of television viewing in early childhood with the subsequent development of asthma. Thorax. 2009;64(4):321–5.PubMedCrossRef
193.
go back to reference Rasmussen F, Lambrechtsen J, Siersted HC, et al. Low physical fitness in childhood is associated with the development of asthma in young adulthood: the Odense Schoolchild Study. Eur Respir J. 2000;16(5):866–70.PubMedCrossRef Rasmussen F, Lambrechtsen J, Siersted HC, et al. Low physical fitness in childhood is associated with the development of asthma in young adulthood: the Odense Schoolchild Study. Eur Respir J. 2000;16(5):866–70.PubMedCrossRef
194.
go back to reference Virchow JC, Crompton GK. Dal Negro R, et al. Importance of inhaler devices in the management of airway disease. Respir Med. 2008;102:10–9.PubMedCrossRef Virchow JC, Crompton GK. Dal Negro R, et al. Importance of inhaler devices in the management of airway disease. Respir Med. 2008;102:10–9.PubMedCrossRef
195.
go back to reference Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration. 2008;75(1):18–25.PubMedCrossRef Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration. 2008;75(1):18–25.PubMedCrossRef
196.
go back to reference Allen SC, Warwick-Sanders M, Baxter M. A comparison of four tests of cognition as predictors of inability to learn to use a metered dose inhaler in old age. Int J Clin Pract. 2009;63(8):1150–3.PubMedCrossRef Allen SC, Warwick-Sanders M, Baxter M. A comparison of four tests of cognition as predictors of inability to learn to use a metered dose inhaler in old age. Int J Clin Pract. 2009;63(8):1150–3.PubMedCrossRef
197.
go back to reference Board M, Allen SC. A simple drawing test to identify patients who are unlikely to be able to learn to use an inhaler. Int J Clin Pract. 2006;60(5):510–3.PubMedCrossRef Board M, Allen SC. A simple drawing test to identify patients who are unlikely to be able to learn to use an inhaler. Int J Clin Pract. 2006;60(5):510–3.PubMedCrossRef
198.
go back to reference Quinet P, Young CA, Héritier F. The use of dry powder inhaler devices by elderly patients suffering from chronic obstructive pulmonary disease. Ann Phys Rehabil Med. 2010;53(2):69–76.PubMedCrossRef Quinet P, Young CA, Héritier F. The use of dry powder inhaler devices by elderly patients suffering from chronic obstructive pulmonary disease. Ann Phys Rehabil Med. 2010;53(2):69–76.PubMedCrossRef
199.
go back to reference MacLaughlin EJ, Raehl CL, Treadway AK, et al. Assessing medication adherence in the elderly: which tools to use in clinical practice? Drugs Aging. 2005;22(3):231–55.PubMedCrossRef MacLaughlin EJ, Raehl CL, Treadway AK, et al. Assessing medication adherence in the elderly: which tools to use in clinical practice? Drugs Aging. 2005;22(3):231–55.PubMedCrossRef
200.
go back to reference Rand CS. Patient adherence with COPD therapy. Eur Respir Rev. 2005;14(96):97–101.CrossRef Rand CS. Patient adherence with COPD therapy. Eur Respir Rev. 2005;14(96):97–101.CrossRef
201.
202.
go back to reference DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3):200–9.PubMedCrossRef DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3):200–9.PubMedCrossRef
203.
go back to reference Horne R. Compliance, adherence, and concordance—implications for asthma treatment. Chest. 2006;130(1 Suppl):65S–72S.PubMedCrossRef Horne R. Compliance, adherence, and concordance—implications for asthma treatment. Chest. 2006;130(1 Suppl):65S–72S.PubMedCrossRef
204.
go back to reference Jenkins L, Britten N, Stevenson F, et al. Developing and using quantitative instruments for measuring doctor-patient communication about drugs. Patient Educ Couns. 2003;50(3):273–8.PubMedCrossRef Jenkins L, Britten N, Stevenson F, et al. Developing and using quantitative instruments for measuring doctor-patient communication about drugs. Patient Educ Couns. 2003;50(3):273–8.PubMedCrossRef
205.
206.
go back to reference Marin L, Colombo P, Bebawy M, et al. Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management. Expert Opin Drug Deliv. 2011;8(9):1205–20.PubMedCrossRef Marin L, Colombo P, Bebawy M, et al. Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management. Expert Opin Drug Deliv. 2011;8(9):1205–20.PubMedCrossRef
207.
go back to reference Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews. 2008;(1):CD000146. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews. 2008;(1):CD000146.
208.
go back to reference Jimenez Ruiz CA, Ramos Pinedo A, Cicero Guerrero A, et al. Characteristics of COPD smokers and effectiveness and safety of smoking cessation medications. Nicotine Tob Res. 2012;17:17. Jimenez Ruiz CA, Ramos Pinedo A, Cicero Guerrero A, et al. Characteristics of COPD smokers and effectiveness and safety of smoking cessation medications. Nicotine Tob Res. 2012;17:17.
209.
Metadata
Title
Managing Older Patients with Coexistent Asthma and Chronic Obstructive Pulmonary Disease
Diagnostic and Therapeutic Challenges
Authors
Vanessa M. McDonald
Isabel Higgins
Peter G. Gibson
Publication date
01-01-2013
Publisher
Springer International Publishing AG
Published in
Drugs & Aging / Issue 1/2013
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-012-0042-z

Other articles of this Issue 1/2013

Drugs & Aging 1/2013 Go to the issue

Adis Drug Evaluation

Duloxetine

Adis Drug Clinical Q&A

Once-Daily Memantine

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine